SDI (Strategic Diagnostics Inc., NASDAQ:SDIX), a leading provider of
biotechnology-based products and services for a broad range of life
science, food safety, and industrial applications, today announced it
has been selected again by Science Applications International
Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for
the National Cancer Institute’s “Clinical Proteomic Technologies for
Cancer” initiative (CPTC: http://proteomics.cancer.gov).
The SDI monoclonal antibodies will serve as reference reagents for the
scientific cancer community.
SDI was selected for a third consecutive time as the key monoclonal
antibody provider. The selection was based on SDI’s life sciences and
antibody expertise, large-scale capacity, standardized processes, and
fully-integrated quality management systems. The National Cancer
Institute’s CPTC will extensively characterize these reagents consistent
with their mission to make available high-quality reagents with baseline
data to research scientists.
CPTC’s goal is to accelerate discovery and clinical research in cancer,
using an integrated approach that assesses and optimizes proteomic
technology measurement capabilities and develops universally accepted
metrics to identify and minimize experimental variability from
run-to-run, instrument-to-instrument, and lab-to-lab. CPTC aims to
achieve this goal by optimizing existing platforms; developing
innovative proteomic technologies and computational tools; and
developing community reagents and resources. Its Proteomic Reagents &
Resources component includes SOPs, data, proteins, and
well-characterized, high-quality antibodies, whose performance
characteristics will be observed at the Antibody Characterization
Laboratory at NCI-Frederick (NCI-F), part of NCI-F’s Advanced Technology
Program.
Commenting on the agreement, Mr. Fran DiNuzzo, SDI’s President and CEO,
said, “SDI is proud to be a key supplier to this important large-scale
cancer research initiative. Being selected for a third consecutive year
by SAIC-F underscores our belief that SDI’s expertise, quality,
infrastructure, and capacity position us as a premier supplier of
comprehensive antibody services. Moreover, as the study of proteins
continues to increase in importance to the research community, and
antibodies continue to be the most widely-used tools for understanding
the molecular dynamics underlying disease, we anticipate a continued
demand for SDI products and services.”